Screener
BridgeBio Pharma BBIO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating activities: | ||
| Net loss | $(166,555) | $(169,608) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 33,242 | 25,882 |
| Net loss from equity method investments | 18,283 | 15,556 |
| Noncash interest expense on deferred royalty obligations (1) | 39,873 | 24,020 |
| Change in fair value of the embedded derivative associated with the deferred royalty obligation | (2,158) | (3,952) |
| Amortization of debt discount and issuance costs | 1,819 | 1,621 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's stock-based comp?
- BridgeBio Pharma (BBIO) reported stock-based comp of $33.24M in Q1 2026.
- How has BridgeBio Pharma's stock-based comp changed year-over-year?
- BridgeBio Pharma's stock-based comp increased by 28.4% year-over-year, from $25.88M to $33.24M.
- What is the long-term trend for BridgeBio Pharma's stock-based comp?
- Over 4 years (2021 to 2025), BridgeBio Pharma's stock-based comp has grown at a 7.5% compound annual growth rate (CAGR), from $99.51M to $133.02M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about BridgeBio Pharma's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude